Multiple sclerosis

41 trials 12 recruiting MedDRA PT
41 Registered trials
12 Recruiting
19 Unique sponsors
34 Unique IMPs
28 Commercial trials
Drug classes (ATC)
— ATC code not specified 20
L Oncology (ATC L) 17
H Endocrinology (ATC H) 5
N Neurology/Psychiatry (ATC N) 6
R Respiratory (ATC R) 5
A Gastroenterology (ATC A) 3
B Haematology (ATC B) 1
P Parasitology (ATC P) 1
Mechanism of action (INN-stem analysis)
Unknown / small molecule 21 substances
Monoclonal antibody (immune, humanized) 2 substances
Interferon 2 substances
GLP-1 receptor agonist 2 substances
Monoclonal antibody (immune) 1 substance
Corticosteroid 1 substance
Analgesic / antipyretic 1 substance
Monoclonal antibody (human) 1 substance
Supportive / diluent 1 substance
Monoclonal antibody (chimeric) 1 substance
Antimetabolite 1 substance
Phase III: 13 Phase II: 13 Phase I/II: 2 Phase IV: 5 Phase I: 1 Phase I (Other): 7

Filter these 41 trials by country, sponsor, date range and more.

Open in Search → Gap analysis →
Show: 41 trials

Phase III

13 trials
  • Celltrion Inc. Commercial
    CETIRIZINE DIHYDROCHLORIDE; METHYLPREDNISOLONE; OCRELIZUMAB; PARACETAMOL
    2022-501622-37-00 6 countries 2024 n=333
    Ended
  • F. Hoffmann-La Roche AG Commercial
    IMP not specified
    2022-502611-10-00 11 countries 2020 n=297
    Ended
  • F. Hoffmann-La Roche AG Commercial
    OCRELIZUMAB
    2023-505974-14-00 20 countries 2022 n=809
    Ended
  • F. Hoffmann-La Roche AG Commercial
    OCRELIZUMAB
    2023-505975-54-00 4 countries 2022 n=153
    Ended
  • F. Hoffmann-La Roche AG Commercial
    DIPHENHYDRAMINE HYDROCHLORIDE; METHYLPREDNISOLONE; OCRELIZUMAB; PARACETAMOL
    2023-506429-13-00 7 countries 2018 n=520
    Ended
  • F. Hoffmann-La Roche AG Commercial
    DIPHENHYDRAMINE HYDROCHLORIDE; METHYLPREDNISOLONE; OCRELIZUMAB; PARACETAMOL
    2023-506467-34-00 10 countries 2020 n=357
    Ended
  • F. Hoffmann-La Roche AG Commercial
    DIPHENHYDRAMINE HYDROCHLORIDE; METHYLPREDNISOLONE; OCRELIZUMAB; PARACETAMOL
    2023-506515-18-00 11 countries 2020 n=310
    Ended
  • F. Hoffmann-La Roche AG Commercial
    DIPHENHYDRAMINE HYDROCHLORIDE; METHYLPREDNISOLONE; OCRELIZUMAB; PARACETAMOL
    2023-506543-41-00 14 countries 2018 n=645
    Ended
  • Novartis Pharma AG Commercial
    SIPONIMOD FUMARIC ACID
    2024-511686-11-00 13 countries 2021 n=64
    Recruiting
  • Sanofi-Aventis Recherche & Developpement Commercial
    IMP not specified
    2023-504358-36-00 18 countries 2024 n=386
    Recruiting
  • Sanofi-Aventis Recherche & Developpement Commercial
    FREXALIMAB
    2023-504359-29-01 13 countries 2024 n=591
    Ended
  • Sanofi-Aventis Recherche & Developpement Commercial
    FREXALIMAB; TERIFLUNOMIDE
    2024-514343-29-00 16 countries 2024 n=410
    Ended
  • Sanofi-Aventis Recherche & Developpement Commercial
    FREXALIMAB
    2024-519304-28-00 3 countries 2026 n=67
    Recruiting

Phase II

13 trials
  • Celgene Corp. Commercial
    CC-97489
    2024-517745-14-00 3 countries 2025 n=100
    Recruiting
  • F. Hoffmann-La Roche AG Commercial
    OCRELIZUMAB
    2024-517980-22-00 5 countries 2025 n=86
    Recruiting
  • F. Hoffmann-La Roche AG Commercial
    OCRELIZUMAB; RO7268489
    2025-521636-10-00 7 countries 2026 n=235
    Recruiting
  • Sanofi-Aventis Recherche & Developpement Commercial
    ODITRASERTIB
    2023-509078-45-00 7 countries 2022 n=157
    Ended
  • Sanofi-Aventis Recherche & Developpement Commercial
    FREXALIMAB
    2024-513527-17-00 5 countries 2021 n=72
    Ended
  • Antwerp University Hospital Academic
    DIMETHYL FUMARATE; FINGOLIMOD; GLATIRAMER ACETATE; INTERFERON BETA-1A; METFORMIN HYDROCHLORIDE; NATALIZUMAB; OCRELIZUMAB; OFATUMUMAB; OZANIMOD; PEGINTERFERON BETA-1A; PONESIMOD; RECOMBINANT INTERFERON BETA-1B; SIPONIMOD; TERIFLUNOMIDE
    2023-503190-38-00 1 country 2023 n=120
    Ended
  • CCAB Centro Clinico Academico Braga Associacao Academic
    MODAFINIL
    2022-501414-53-00 1 country 2024 n=64
    Recruiting
  • Comenius University Bratislava Academic
    DULAGLUTIDE; SEMAGLUTIDE
    2024-519235-42-00 1 country n=1
    Pending
  • Fundacio De Recerca Clinic Barcelona-Institut D’Investigacions Biomediques August Pi I Sunyer Academic
    AUTOLOGOUS TOLEROGENIC DENDRITIC CELLS
    2024-519975-24-00 1 country 2025 n=45
    Ended
  • Helse Bergen HF Academic
    MESENCHYMAL STROMAL CELLS, EX VIVO CULTURED; SODIUM CHLORIDE
    2023-510228-63-00 1 country 2024 n=18
    Recruiting
  • Region Uppsala Academic
    IMP not specified
    2024-519700-28-01 1 country n=50
    Pending
  • Varsinais-Suomen hyvinvointialue Academic
    HYDROXYCHLOROQUINE SULFATE
    2025-522573-11-00 1 country n=34
    Pending
  • Wojskowy Instytut Medyczny Panstwowy Instytut Badawczy Academic
    LACTOBACILLUS HELVETICUS, LACTOBACILLUS RHAMNOSUS, STRAIN LCR35, LIVE; OFATUMUMAB; OZANIMOD; OZANIMOD, OZANIMOD
    2025-520955-10-00 1 country n=210
    Not authorised

Phase I/II

2 trials
  • Miltenyi Biomedicine GmbH Commercial
    IMP not specified
    2024-517601-82-00 1 country 2026 n=25
    Recruiting
  • Assistance Publique Hopitaux De Paris Academic
    IMP not specified
    2023-507874-42-00 1 country 2024 n=80
    Halted

Phase IV

5 trials
  • F. Hoffmann-La Roche AG Commercial
    OCRELIZUMAB
    2024-510974-25-00 2 countries 2021 n=10
    Ended
  • Amsterdam UMC Academic
    OCRELIZUMAB; RITUXIMAB
    2022-502664-21-00 1 country 2023 n=200
    Ended
  • Fakultni Nemocnice Ostrava Academic
    OCRELIZUMAB
    2024-514549-12-00 1 country 2025 n=100
    Recruiting
  • María Luisa Martínez Ginés Academic
    CLADRIBINE
    2023-504577-21-00 1 country n=20
    Expired
  • Varsinais-Suomen hyvinvointialue Academic
    CLADRIBINE
    2024-519921-39-00 1 country 2019 n=15
    Ended

Phase I

1 trial
  • F. Hoffmann-La Roche AG Commercial
    IMP not specified
    2023-509357-31-00 7 countries 2021 n=55
    Recruiting

Phase I (Other)

7 trials
  • Celgene Corp. Commercial
    IMP not specified
    2023-507820-22-00 4 countries 2024 n=56
    Halted
  • F. Hoffmann-La Roche AG Commercial
    IMP not specified
    2023-506863-32-00 2 countries 2023 n=5
    Ended
  • F. Hoffmann-La Roche AG Commercial
    IMP not specified
    2024-513639-26-00 5 countries n=44
    Ended
  • Immunic AG Commercial
    IMP not specified
    2025-521754-41-00 1 country 2025 n=24
    Ended
  • Immunic AG Commercial
    IMP not specified
    2025-523791-24-00 1 country 2026 n=28
    Ended
  • Immunic AG Commercial
    IMP not specified
    2026-525208-90-00 1 country 2026 n=26
    Recruiting
  • Novartis Pharma AG Commercial
    IMP not specified
    2023-506760-13-00 1 country 2023 n=16
    Ended
Sponsor activity
SponsorTypeTrialsPhasesRecruiting
F. Hoffmann-La Roche AG Commercial 13 Phase I, Phase I (Other), Phase II, Phase III, Phase IV 3
Sanofi-Aventis Recherche & Developpement Commercial 6 Phase II, Phase III 2
Immunic AG Commercial 3 Phase I (Other) 1
Celgene Corp. Commercial 2 Phase I (Other), Phase II 1
Novartis Pharma AG Commercial 2 Phase I (Other), Phase III 1
Varsinais-Suomen hyvinvointialue Academic 2 Phase II, Phase IV 0
Celltrion Inc. Commercial 1 Phase III 0
Miltenyi Biomedicine GmbH Commercial 1 Phase I/II 1
Antwerp University Hospital Academic 1 Phase II 0
CCAB Centro Clinico Academico Braga Associacao Academic 1 Phase II 1
Comenius University Bratislava Academic 1 Phase II 0
Fundacio De Recerca Clinic Barcelona-Institut D’Investigacions Biomediques August Pi I Sunyer Academic 1 Phase II 0
Helse Bergen HF Academic 1 Phase II 1
Region Uppsala Academic 1 Phase II 0
Wojskowy Instytut Medyczny Panstwowy Instytut Badawczy Academic 1 Phase II 0
Amsterdam UMC Academic 1 Phase IV 0
Fakultni Nemocnice Ostrava Academic 1 Phase IV 1
María Luisa Martínez Ginés Academic 1 Phase IV 0
Assistance Publique Hopitaux De Paris Academic 1 Phase I/II 0
New trials by year
2019
1
2020
3
2021
4
2022
3
2023
4
2024
8
2025
5
2026
5
← All indication landscapes